In this review:
Include ECE status in melanoma classification systems?
Adjuvant dabrafenib + trametinib in BRAF V600E/K-mutant melanoma
. . . which patient subgroups benefit most?
Nivolumab ± ipilimumab active in melanoma brain metastases
Avelumab: durable antitumor activity in Merkel cell carcinoma
A gene-signature based risk score identifies thin fatal melanomas
Melanoma antigens: biomarkers for immunotherapy response?
BRAF mutation linked to SLN positivity and CNS metastasis
Assessing optimal radiological surveillance for high-risk melanoma
IT-pIL-12-EP + pembrolizumab in metastatic melanoma
Please login below to download this issue (PDF)